Clinical Trials
12 trialsNCT07109726 2026-05-22
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
Phase 1/2 Recruiting
NCT07602842 2026-05-22
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
InduPro, Inc.
Phase 1/2 Not yet recruiting
NCT07189871 2026-03-27
BetaBart
Radiopharm Theranostics, Ltd
Phase 1/2 Recruiting
NCT06747585 2026-03-03
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Alentis Therapeutics AG
Phase 1/2 Recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT04868877 2026-02-19
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Merus B.V.
Phase 1/2 Active not recruiting
NCT05914116 2025-11-21
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1/2 Recruiting
NCT06975410 2025-08-01
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Yuhan Corporation
Phase 1/2 Recruiting
NCT05144698 2025-05-14
RAPA-201 Therapy of Solid Tumors
Rapa Therapeutics LLC
Phase 1/2 Recruiting
NCT05473156 2025-03-26
APT-CUBE
AP Biosciences Inc.
Phase 1/2 Recruiting
NCT04721223 2024-09-19
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2 Completed
NCT02915432 2021-12-13
The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Unknown